S Mosquirix
Selected indexed studies
- Mosquirix™ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy. (Vaccines (Basel), 2022) [PMID:35632469]
- RTS,S/AS01 malaria vaccine (Mosquirix(®)): a profile of its use. (Drugs Ther Perspect, 2022) [PMID:36093265]
- The Mosquirix (RTS.S) malaria vaccine. (Trop Doct, 2020) [PMID:32370683]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Malaria Vaccines: Progress to Date. (2023) pubmed
- RTS,S/AS01E malaria vaccine (MoSQUIRIX*) Children living in malaria-endemic regions: little efficacy, poorly documented harms. (2017) pubmed
- Mosquirix™ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy. (2022) pubmed
- RTS,S/AS01 malaria vaccine (Mosquirix(®)): a profile of its use. (2022) pubmed
- The Mosquirix (RTS.S) malaria vaccine. (2020) pubmed
- Mosquirix (RTS,S): a novel vaccine for the prevention of Plasmodium falciparum malaria. (2012) pubmed
- RTS,S/AS01 vaccine (Mosquirix™): an overview. (2020) pubmed
- Current approaches to malaria vaccines. (2022) pubmed
- Towards Eradication of Malaria: Is the WHO's RTS,S/AS01 Vaccination Effective Enough? (2021) pubmed
- A candidate antibody drug for prevention of malaria. (2024) pubmed